Keith Jones

We had the pleasure of speaking to the inimitable Gordon Sanghera, co-founder and CEO of Oxford Nanopore Technologies, valued at around $6.8bn in 2021. Gordon somewhat accidentally ended up as an entrepreneur, breaking the conventional VC wisdom around 'born founders'. The technology is wild - democratising access to genomic sequencing giving us a new understanding of living organisms. In the episode of Riding Unicorns, we cover: 00:00 Defining Entrepreneurship 00:55 Understanding Oxford Nanopore's Technology 06:10 Gordon's Journey to Founding Oxford Nanopore 12:09 Commercialization Challenges and Strategies 16:27 Building a Strong Founding Team 20:55 Navigating the Ups and Downs of Deep Tech 25:54 Innovative Applications of Nanopore Technology 28:57 Company Culture and Operational Insights 35:05 Attracting Talent in a Competitive Market 37:22 The IPO Experience and Future Outlook https://lnkd.in/eQZVSGeK

18

1 Comment

I couldn’t be prouder to be a Venture Partner at Isomer Capital (aka the best European FoF - at least for me) as we just announced the launch of our pioneering £100m secondaries fund. This fund is dedicated to acquiring stakes from LPs in various VC funds, tapping into a massive and largely unexplored market. 🌟 Key Highlights: - Focused Investment: Primarily targeting stakes in VC funds, with selective investments in private companies. - Robust Funding: Already over 20% funded, thanks to strong support from Nordic family offices and a German foundation. - Market Potential: With a growing number of private tech companies and a VC liquidity crunch, Europe's VC secondaries market is poised for rapid growth. - Track Record: This isn’t Isomer’s first foray into the secondaries market. As a firm we’ve done several secondaries deals with portfolio companies and VC firms, including early-stage VC Seedcamp (in 2021) and mobility giant Bolt (in 2023). - Expert Team: Welcoming the amazing Omolade (Rachel) A., formerly of Coller Capital, as a principal to lead this initiative. 💡 Investment Strategy: - 65-75% of the fund will buy "LP interest" stakes in VC funds. - 15-25% will be directed towards stakes in companies. - Up to 15% reserved for flexible investment opportunities. 📈 Looking Ahead: We're targeting returns of 2-3x, with significant distributions expected in the next 4-7 years. As one of the few players in this space, we're not just participating in the market—we're driving it forward. Read all about it here: https://lnkd.in/dc7sbC3G #VentureCapital #SecondariesFund #EuropeanVC

23

1 Comment

"Funding Collapse sends investment in start-ups to six year low" The Times today covering the shocking stats that VenturePath uncovered, with our partner Beauhurst. Great quotes from supporters Michael Moore CEO, BVCA and Julian David CEO, techUK. * UK VC funding at Series A is -44% from last year, and worsening * Q3 24 is down a staggering 57% from Q2, itself down from Q1 * 9 in 10 seed funded startups cannot access Series A VC funding, the next 'rung on the funding ladder' * Just 32 future scaleup companies across the whole of the UK were able to access their first VC funding round in Q3...a 6 year low * Half a billion less capital is going in to UK scaleups at Series A, than just 2 years ago! As the UK scaleup funding gap widens, we are losing ground against other countries, at both startup stage (a position the UK worked hard to achieve, since 2011), and for scaleup support. OECD data: 13th in the world for scaleup support, and that's before Series A funding access dried up. I get that its confusing. Another report (BBB, Nations & Regions) released this week spoke of positive trends in private investment, stating "The data for Q2 2024 shows that investment value has continued to grow". Great, I love to see optimistic data. But under analysis that bundles venture with private equity (later stage), where a few megadeals skew the numbers. Otherwise the exact opposite is true. Our independent research here, for the UK ScaleUp Investment Mission, is laser beam focussed on Series A. The funding round where companies move from the c.1m startups launched each year, through the 2,179 that access seed funding, into the rarefied category of being recognised as future scaleups, attracting Series A funding (£2-10m). The UK venture landscape is currently funding just 248 pa of these companies, and declining. We've been sharing this urgent call for support with the new Government since the day after the election. I've personally met with several Ministers, and spoke to all the relevant Government departments. I will shamelessly repeat loudly what is at stake. UK scaleup funding at Series A has nearly halved in a year, and continues to decline steeply, more than halving in the last quarter. VenturePath developed The UK ScaleUp Investment Mission to convene the scaleup support ecosystem and £7bn of funders to help address this problem, to improve nationwide access to VC investment, and create more venture-backed successes. We have clear support, clear recommendations to reverse this decline in UK scaleup investment, and have made a clear ask of Government for participation in this, to ensure immediate action is taken to create the conditions for success for UK scaleups, ensuring the focus on growth isn't undermined by lack of capital, or equitable access to it. Government decision makers, we'd love your interest, to progress to action. HM Treasury: Rt Hon Rachel Reeves Spencer Livermore James Murray & CC Poppy Gustafsson (welcome to the debate).

738

195 Comments

Taavet Hinrikus and I made the Financial Times Due Diligence email. https://lnkd.in/ez2AuGQx One 'unintended consequence' is that if there is a 45% tax on carry and CGT (raising £40m per year, remember) it for all intents and purposes closes the door on new VCs in the UK. Especially started by teams from non-traditional backgrounds. To meet the GP commit, you need to be already part of the 'wealthy' as you cannot rely on the value you create - nearly half of it will disappear - to fund it. We have both had extremely successful startups which are few and far between. The smaller number of new VCs will therefore more likely increasingly be for people who have inherited the capital or can draw it from their already rich family. Probably not want they have in mind with this policy.

32

2 Comments

📊 Investing in Innovation: With the UK gearing up for the July 2024 general election, the investment landscape is evolving rapidly. In today’s discussion, Edward from West Hill Capital and I delve into the types of companies ready for investment beyond just tech. We explore the importance of innovation and unique selling points in attracting equity funding. If you’re looking to raise investment or need support within your business, book time with me: https://lnkd.in/e8Wf2TTa #StartupInvesting #Innovation #UKPolitics #Entrepreneurship

17

#TransformativePotential As the UK government considers backing consolidating pension pots into large, pooled funds (Pension mega funds), we face a remarkable opportunity. Biomedical mega funds could bridge the "Valley of Death" in drug development while offering stable investor returns. But how can such a bold model manage risks while amplifying returns? #InnovativeStructuring The solution lies in sophisticated financial engineering. Through tranches, investments are segmented for different risk appetites: senior tranches offering 5-6% fixed returns for pension funds, mezzanine tranches balancing moderate risk with higher yields, and equity tranches absorbing first losses but providing outsized returns. But how do we ensure resilience against systemic shocks? The answer lies in correlation modeling. By understanding the relationships between different drug projects, funds can optimize their portfolios, balancing high-risk correlated projects with independent ones. This approach safeguards returns, even when regulatory delays or market disruptions hit specific therapeutic areas. #MonetizeEarly, Can we generate returns before a drug reaches the market?  Early-stage monetization generates returns before market approval through licensing agreements, partnerships, and asset sales. A Phase II oncology drug could generate $200M upfront plus milestone payments, creating immediate cash flows. #SteadyFlows How do we ensure consistent returns in such a high-risk industry? Reserve funds act as crucial buffers while a staggered portfolio strategy spreads investments across late-stage (3-5 years), mid-stage (5-7 years), and early-stage projects (7-10 years), ensuring steady cash flows. #GovernmentSupport Public sector backing through credit enhancements and guarantees reduces default risks. Third-party guarantees with insurers provide additional security, aligning healthcare innovation with financial sustainability. #LeveragedReturns, Can we amplify returns while managing risk? Asset-backed securities (ABS) leverage royalty streams from approved drugs for additional capital. The LifeArc-CPPIB Keytruda deal ($1.3B) demonstrates this approach's potential. #BreakthroughPotential A portfolio of 100+ oncology projects improve breakthrough odds dramatically. Even for Alzheimer's research, structured funds (Portfolio Optimisation) could unlock $5B annual revenues from successful treatments. #CollaborativeInnovation Cancer Research UK (CRUK) Cancer Research Horizons  , LifeArc Ventures, and research organisations etc could collaborate within this framework, accelerating patient access while optimising returns. This creates a virtuous cycle of innovation and investment. Through careful structuring, risk management, and innovative financing, we might finally bridge the "Valley of Death" in drug development. #UKpensionmegafund #UKpooledpensionpots #tranches #securitization #financialengineering #portfolioptimisation #seniortranches #ABS #investment #VCs

3

1 Comment

🎉 20VC Closes Fund III at $400M to Back Next-Gen Startups London-based venture capital firm 20VC, led by Founder and Managing Partner Harry Stebbings, has closed its third fund at a remarkable $400 million. Known for combining venture capital expertise with a powerful media platform, the firm continues to solidify its position at the forefront of the startup ecosystem. 💰 The Fund Breakdown: - $125M allocated for Seed investments, ranging from $100K to $3M. - $275M dedicated to Series A investments, ranging from $5M to $15M. Backers of the fund include renowned institutions such as MIT Investment Management Company, Horsley Bridge Partners, and RIT Capital Partners plc. 🚀 The 20VC Difference 20VC operates three sub-funds: 20Sales, 20Growth, and 20Product—each supported by top-tier experts from global tech giants. These specialists actively assist portfolio companies in scaling and achieving their full potential. The firm's innovative approach extends beyond traditional VC, leveraging its media platform, which features in-depth conversations with prominent figures from the business and venture capital worlds, fostering a unique blend of investment and insight. 🌟 Key Team Members Harry Stebbings – Founder & Managing Partner Kieran Hill – Partner, Pre-Seed & Seed Paul Bonnet – General Partner, Series A & Growth This latest fund positions 20VC to further support transformative startups, enabling them to grow from the earliest stages to impactful global players. ✅ Looking to raise capital for your #VCfund?   🤝 Need warm #LP introductions?   📝 Selling #secondaries to increase liquidity?   🧐 Looking for co-investments (Series A/Series B)?   ▶ Please use G+QUANT's link for inquiries and fund decks, or send your inquiry directly to [email protected] #VentureCapital #20VC #StartupFunding #SeedStage #SeriesA #VCNews #Innovation #TechInvestments #StartupEcosystem #Founders

166

10 Comments

VC Industry Data coming out much earlier this year!!! Let us get you up to speed on: levels of fundraising, exits achieved; investment trends; sectors attracting the most capital; and so much more. Interested in joining us for the VC Industry Survey Launch and sharing your industry perspectives? Please register your interest below. See you there!

4

Numbers & insights from a deep tech venture studio that launched 11 companies (all are active) in the last 7 years, reaching £85M valuation across the portfolio: 1. Post Urban, initially bootstrapped by Luke Robinson, an academic with a PhD in physics from Cambridge, now operates with external funding from a UK-based fund. 2. Launched 5 companies during the first 5 years and 6 companies during the last 2 years. 3. All 11 completed pre-seed rounds; 1 of them got Series A, 2 of them are approaching their Series A. 4. The startups have collectively raised ~£25M in venture capital, in addition to receiving grants. The total valuation of the 11 companies is ~£85M, half of which have not yet undergone subsequent funding rounds. 5. Initial equity splits: the venture builder 20%, CEOs of startups 35% (vests over 4 years), CTOs – 20-25%, employees 10-15%. 6. The initial valuation of startups was £2 million, with £300K invested by the venture builder. The last 2 startups were at £3.5-4M initial valuation. 7. Building deep tech ventures requires significantly higher initial funding because these projects need more time to develop demonstrable products. Two portfolio companies hit £1M in ARR. 8. The venture builder has increased the capital for the last 2 startups to ensure they reach meaningful milestones. The CEOs of the startups were able to secure additional funding through their networks, £350K and £450K, respectively. 9. The deep tech investor pool is smaller than that for sectors like SaaS, which requires a stronger proof of concept and market readiness to attract funding. 10. 3-4 times, potential customers became investors in Post Urban Ventures. This is a great approach because it secures investment and validates the concept by gauging whether these potential customers truly believe in the solution and its market necessity. 11. They don't start with a technology or an idea; instead, they integrate insights about global problems and, by actively engaging with advisory boards, founders, and industry experts, identify pain points and align them with technological solutions. 12. They do not bring universities in as co-founders but source scientists or professors to contribute to research and development. This involves leveraging academic expertise to support the technical aspects of startup projects until a prototype is developed. 13. The studio maintains strong connections with major academic institutions, including Cambridge, Oxford, Imperial College, and UCL, supporting its deep tech focus and facilitating access to new technologies and potential founders. 14. Areas of focus in deep tech: AI (Knowledge Graphs, NLP, DNNs, Computer Vision, Edge AI, Active Learning), Quantum Technologies, Biotech, AgTech, Enterprise SaaS. Watch the full interview to gain insights into the portfolio companies, handling IP collaborations with universities, key challenges, and team construction: https://lnkd.in/dCi7fZ7G

48

5 Comments

In vitro diagnostics for early cancer detection has often been a graveyard for investors. Investors are attracted by the undoubtedly huge market potential. If a company can develop a diagnostic test that is implemented as a population level screening tool, this is the definition of a venture scale opportunity. However, multiple factors are at play that make the journey far from easy. You need a highly sensitive and specific test that allows you to minimise false positives and false negatives. This is because the burden of over diagnosis and over treatment against a change in overall mortality rates is a finely tuned balancing act. You'd also want to ensure that the screening tool was applicable to multi-cancer detection, going further than just a rule-out test, by predicting the origin site of a particular cancer. As a pre-seed/seed investor what we are often looking for is deep scientific domain expertise, coupled with credibility to achieve a proof-of-concept data point and/or prototypes. Our latest investment at Empirical Ventures into Xgenera and the dynamic duo Dr Andy Shapanis and Prof Paul Skipp might just be the right starting point for approaching this opportunity. Their multi cancer early detection test (MCED) called miONCO was developed from analysing relative expression profiles of microRNAs in 20,000 patient samples. Xgenera’s two step test would detect cancer using a computational algorithm to identify microRNA profiles extracted from patient blood samples, and can predict the site of origin of the cancer. As a screening test this could improve patient lives significantly. I believe Xgenera has the right technology, at the right time, based around recent advances in computational speed and power, post-COVID knowledge moats related to qPCR scale-up and novel biomarkers such as microRNAs to capitalise on this potential. Read more about it below. I can't wait to join the board to support the team as they navigate the 0 to 1 phase of this journey. CAPITAL AT RISK. FOR PROFESSIONAL INVESTORS ONLY. https://lnkd.in/dNpuSERg

41

1 Comment

Scale-up business guide to getting investor-ready: THE FINANCIALS (2/7) Before approaching investors, you need to get your management accounts and everything associated with how you make money and spend money in order. This article explains the essentials of your business’ financials. #Business #investorready #financials

1

What to Include in a Data Room for Investors? — Advice From VC Fund GP https://buff.ly/4eEUahI Investors look for comprehensive data rooms to make informed decisions. A well-organized data room should include financial statements, legal documents, market analysis, and growth projections. Providing detailed information on past performance and future strategies is crucial. Additionally, incorporating visual aids like charts and graphs can enhance understanding. According to a study by PwC, data rooms with thorough documentation increase investor confidence by 40%. Ensuring the data room is secure and easily accessible is also essential. #InvestorRelations #DueDiligence

4

1 Comment

Today we have a superb episode with an absolute legend, Alan Patricof, Co-Founder of Primetime Partners, Greycroft, and Apax Partners. It’s hard to explain just how important Alan has been for tech and VC. He’s one of the true pioneers in venture capital worldwide, having started his first VC firm in the 1970s, Alan Patricof and Associates, which later became Apax Partners and currently has over ~$80Bn AUM. Alan is an inspiring figure, not only because of his success in the business world but also because of his vitality and contagious optimism. He joined us a day after his 90th birthday and candidly, he had more energy than most people I know. We recorded live on stage at Rise, created by Barclays in NYC for the 2024 Gilgamesh Ventures Summit, an annual meeting where we gather over 150 limited partners, founders, investors, and friends for a series of events and discussions about the future of tech and financial services. In this episode, we discuss: - The early days of Venture Capital and Tech in the 1970s and beyond - Alan grew up in NYC and built his career in NY – how was the city back then? - Building primetime partners to invest in the fastest growing market, people over 60 - Staying healthy. How Alan keeps fit, focused and is closing deals at 90 Years Old - Why your reputation is all that matters in this business… and a lot more! Special thanks to Morgan Borer, Jessica Schaefer, Carlee Snyder, Courtney Dawson, and Carina Oriel! https://bit.ly/4g1HNMU

67

5 Comments

You can now see news on when a fund has raised on shipshape.vc. Something we have been really excited about for a while. This helps you see: 💰 is a fund likely to have dry powder ⏳️ where a fund is likely to be in their deployment lifecycle* 🕳 whether their absence of deployment (investment) activity might be due to not having raised a fund recently 📰 check the original news source When you add this to existing features like seeing recent deployments, and where we have seen evidence the fund can lead rounds, we think this can save a lot of time in investor discovery/research. Caveats: * this won't apply/help with evergreen funds like Augmentum Fintech - who have a different structure (thanks Georgie Hazell Kivell for the early note on this) - our data coverage is improving but not perfect. The absence of evidence should not be interpreted as evidence of absence - but you can check the evidence we have from the original source. thoughts/feedback welcomed as always #capitalraising #startups #fundraising #founders #venturecapital #investors #vc #vcfunding #technology #startup #tech

56

9 Comments

The market is notoriously difficult for start ups but can be equally challenging for scaling and venture stage businesses. The risks of getting it wrong are not just that you don’t raise enough funds but also giving away too much equity, incurring high investor costs or relying on an investor who is unsupportive. To minimise these risks here are our top ten tips for raising funds. https://lnkd.in/exmfgrdD #scaleups #venturefunding #investmentfunds

4

Owning a niche and solving key customer needs, the key to DeepTech Commercialisation? At Empirical Ventures, we often encounter groundbreaking scientific innovations facing a dual challenge: - Developing novel technology - Proving that this technology solves a pressing market problem For startups, one crucial factor that is often overlooked is speed of execution. Talent and intellectual property are all critically important, but the ability to move swiftly is what allows startups to enter new markets before incumbents. In DeepTech, focusing on a market niche perfectly aligns with the benefits of speed. Examples of niches in DeepTech: Performance Niche - These customers adopt new technologies to outperform competitors or showcase their innovation capabilities to outside stakeholders. Bottom-Line Niche - These customers face immediate pressures that impact their profitability and are motivated to engage with emerging solutions. Silveray’s recent funding round exemplifies these dynamics perfectly. Their flexible digital X-ray detectors have broad potential across industries. However, it is their traction in the aerospace sector and specifically weld inspection that got us excited. For Silveray the niche is driven by two critical factors: Regulatory Pull: Upcoming legislation mandates the digitization of existing and future X-ray film records. Cost Savings: Silveray’s solution delivers significant financial benefits, making it highly attractive to customers facing bottom-line pressures. Silveray have the only viable solution for the digitisation of industrial weld monitoring. With only moderate penetration of this market (<2%) we believe they could generate 8 figure revenues by 2030. This nicely highlights that niche's can be lucrative in the right industries. Great to welcome Dan Cathie and the team at Silveray to the EV portfolio. Looking forward to supporting them as they continue to grow. CAPITAL AT RISK, FOR PROFESSIONAL INVESTORS ONLY

22

3 Comments

Incredible to see Mosaic in the Financial Times this morning in this excellent piece by Sujeet Indap on tech innovation in private equity. Sujeet's research into the historical evolution of Wall Street's analytical horsepower was particularly fascinating. Though I wasn't around for the shift from pen-and-paper to VisiCalc, I can only imagine the step-function productivity increase it unlocked. Anders' assertion that the advent of the spreadsheet in part drove the LBO boom of the late '80s is also intriguing (although I'm sure the <10% min. equity helped, too). Though the spreadsheet was a great advancement in the '80s, it always baffled me that ~30 years later (when I began my PE career) we were still underwriting billion-dollar buyouts using a generic productivity tool and not an industry-focused application. That's precisely why I started Mosaic. With dedicated platforms like Mosaic and Blackstone's Atlas now powering new deal underwriting - could the industry benefit from a similar step-function productivity increase? Also - an open question to anyone who was working as an investment professional in the 1980s/1990s: was the spreadsheet initially met with hesitation / skepticism by a subset of old-school investors who thought there was value in grinding it out until 3am with only pencil and abacus in hand? We're fortunate at Mosaic to work with some of the world's most forward-thinking investors who readily embrace change - but this sentiment does comes up once in a while. What happens to the holdouts? And curious how the innovators - whose shoulders we stand on - navigated it before us. Read the full story here: https://on.ft.com/4dXEvth

122

8 Comments

How do you drive value when fundraising? In the absence of a clear guide, many founders and their boards will chart a steady and linear progression in value, supported by revenue or profit growth, starting at the implied valuation of the initial investment and heading towards a target valuation with valuation reference points to validate this approach. In determining the target value it is worth remembering that business values for scaling growing businesses are typically derived by considering three different methodologies - find out more in this article. https://lnkd.in/e4CH-HH7 #fundraising #valuecreation #investments

3

Tech companies employing over 6400 people globally have used shipshape.vc for their investor research since April (when we started asking for team size)! 💹 Combined revenues of £330m 💷 Capital requirements of £1.8bn 🏦 Companies are valued at £7.5bn 🤯 #capitalraising #startups #fundraising #founders #venturecapital #investors #vc #vcfunding #technology #startup #tech

30

2 Comments